OMNIlife science, Inc. Appoints Steven Nunes As Vice President Of Market Development

EAST TAUNTON, Mass., Jan. 13, 2015 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI"), an established medical technology company targeting the $15 billion and rapidly growing global hip and knee replacement medical device sector, appointed Steven Nunes to the newly created position of Vice President of Market Development, effective January 12, 2015.  In this role, Mr. Nunes will be responsible for all market development activities related to OMNINAV robotic total joint replacement surgery.

Mr. Nunes brings more than 30 years of broad sales and marketing management experience at emerging growth medical device companies. Most relevant to OMNI is his experience as Senior Vice President of Sales and Marketing at MAKO Surgical. During his tenure at MAKO, Mr. Nunes led the sales and marketing effort which resulted in orthopedic robotic and hip and knee implant product revenue growth from $0.5 to $85 million during a four year time span.  MAKO was ultimately acquired by Stryker Corp. for $1.65 billion.

Rick Randall, Chief Executive Officer of OMNI, commented, "I am excited to have Steve guiding the robotic market development effort at OMNI.  OMNI's success is dependent on effective surgeon prospecting, training and adoption of the OMNINAV robotic total joint replacement surgical system. Steve's prior experience in the nationwide establishment of Robotic Assisted Arthroplasty Center of Excellence Programs will help to ensure more patients, surgeons and hospitals can benefit from the improved clinical outcomes delivered through the use of this sophisticated technology and world class implants."

Regarding his new role at OMNI, Mr. Nunes commented, "I was attracted to OMNI because I was particularly looking forward to expanding the growth of OMNINAV, the only FDA cleared surgical robotic system designed to enhance the surgeon's implant placement for total knee replacements. After more than 4,500 procedures in the U.S., I believe OMNI's robotic technology is positioned to deliver the significant value to patients, surgeons, hospitals and all other stakeholders in the healthcare system."

About OMNIlife science, Inc. (OMNI)

OMNI is a privately held company with a proprietary robotic navigation platform, OMNINAV, which allows surgeons to conduct patient specific total knee surgery designed to enhance patient satisfaction, reduce hospital costs, and remove need for MRI and x-rays.  This technology provides surgeons the much needed option to adjust during the procedure and is designed to provide an accurate customized fit.  OMNI is an innovative and well-established hip and knee implant replacements engineering, manufacturing and distribution support company and is focused on providing cutting edge technologies to improve patient care.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., (OMNI) including its advance robotic plans and statements using the terms "plans," "confident" or similar expressions are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release

Contact:

OMNIlife science, Inc. (OMNI)
Kirsten Wyzanski
Director, Marketing Communications
Phone: (774)226-1892

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omni-appoints-steven-nunes-as-vice-president-of-market-development-300019834.html

SOURCE OMNIlife science, Inc.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.